UNCY Stock — Unicycive Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$5.19

Market cap

$142.48M

Price action

19 metrics

Price change (1W)

-7.7%

Price change (30D)

-0.1%

Price change (3M)

-30.2%

Price change (6M)

-25.5%

Price change (YTD)

-12.5%

Price change (1Y)

+20.5%

Trailing year

Price change (5Y)

—

52-week high

$8.56

52-week low

$3.74

Change from 52-week high

-41.0%

Change from 52-week low

+35.0%

Annualized volatility

78.1%

Beta

1.1

RSI (14D)

41.1

Price vs SMA 50

-8.8%

Price vs SMA 200

-21.4%

Avg volume (3M)

1.49M

Relative volume

0.5

Average dollar volume

$8.69M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

27.86M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

217.3×

reciprocal yield 0.5%

P / book

2.8

reciprocal yield 36.3%

FCF yield

—

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-24.0%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

—

Profitability

9 metrics

Gross margin

—

Operating margin

-3,077.6%

Trailing 12 months

Net margin

-4,525.0%

Gross profit (TTM)

—

Operating profit (TTM)

−$33.14M

Net income (TTM)

−$35.22M

Trailing 12 months

Diluted EPS (TTM)

$-1.25

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-3.14

Growth

11 metrics

Revenue growth YoY

-29.0%

Year over year

Net income growth YoY

—

Revenue (TTM)

$675,000

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+118.8%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-66.1%

Return on assets

-48.9%

Debt / equity

—

Current ratio

3.8

EBITDA (TTM)

—

Free cash flow (TTM)

—

Quick ratio

—

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$61.42M

Latest balance sheet

Cash & equivalents

$44.19M

Total assets

$72.03M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$27.84M

Capital expenditures (TTM)

$16,000

R&D (TTM)

$9.60M

SG&A (TTM)

$701,000

Stock compensation (TTM)

$5.14M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

80

13F filer change QoQ

+29

Institutional ownership

50.0%

Short interest

3 metrics

Short interest

14.9%

Latest settlement · 5.5 days to cover

Days to cover

5.5d

Short-squeeze score

71 / 100

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

UNCY · Unicycive Therapeutics, Inc.

UNCY metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search